UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy

被引：0
|
作者：
Qianqian Yu
Tao Zhang
Conghua Xie
Hong Qiu
Bo Liu
Liu Huang
Ping Peng
Jueping Feng
Jigui Chen
Aihua Zang
Xianglin Yuan
机构：
[1] Huazhong University of Science and Technology,Department of Oncology, Tongji Hospital, Tongji Medical College
[2] Huazhong University of Science and Technology,Cancer Center, Union Hospital, Tongji Medical College
[3] Wuhan University,Department of Radiation and Medical Oncology, Zhongnan Hospital
[4] Huazhong University of Science and Technology,Department of Oncology, PuAi Hospital, Tongji Medical College
[5] Wuhan 8th Hospital,Department of Surgery
[6] Hubei Cancer Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 82卷
关键词：
Polymorphism; Irinotecan; Outcome; Metastatic colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：87 / 98
页数：11
相关论文
共 50 条
  • [31] Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis
    Zhu, Xiaoyun
    Ma, Ruchao
    Ma, Xin
    Yang, Gang
    BIOSCIENCE REPORTS, 2020, 40
  • [32] Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy
    Bai, Yu
    Wu, Ai-wei
    Ma, Xu
    Liu, Ying
    Zhang, Yan-hua
    ONCOTARGETS AND THERAPY, 2017, 10 : 3071 - 3081
  • [33] Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy
    Liu, Xing-Han
    Lu, Jun
    Duan, Wei
    Dai, Zhi-Ming
    Wang, Meng
    Lin, Shuai
    Yang, Peng-Tao
    Tian, Tian
    Liu, Kang
    Zhu, Yu-Yao
    Zheng, Yi
    Sheng, Qian-Wen
    Dai, Zhi-Jun
    JOURNAL OF CANCER, 2017, 8 (04): : 691 - 703
  • [34] UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan
    Carlini, LE
    Meropol, NJ
    Bever, J
    Andria, ML
    Hill, T
    Gold, P
    Rogatko, A
    Wang, H
    Blanchard, RL
    CLINICAL CANCER RESEARCH, 2005, 11 (03) : 1226 - 1236
  • [35] Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly
    Alliot, C
    Barrios, M
    BRITISH JOURNAL OF CANCER, 2004, 90 (10) : 2050 - 2051
  • [36] Outcomes of Irinotecan-Based Chemotherapy Regimens in Elderly Medicare Patients With Metastatic Colorectal Cancer
    Obeidat, Nour A.
    Pradel, Francoise G.
    Zuckerman, Ilene H.
    DeLisle, Sylvain
    Mullins, C. Daniel
    AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY, 2009, 7 (06): : 343 - 354
  • [37] Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy
    Hesketh, Paul J.
    Bosnjak, Snezana M.
    Nikolic, Vlada
    Rapoport, Bernardo
    SUPPORTIVE CARE IN CANCER, 2011, 19 (12) : 2063 - 2066
  • [38] Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy
    Paul J. Hesketh
    Snezana M. Bosnjak
    Vlada Nikolic
    Bernardo Rapoport
    Supportive Care in Cancer, 2011, 19
  • [39] Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1
    Sakaguchi, S.
    Garcia-Bournissen, F.
    Kim, R.
    Schwarz, U. I.
    Nathan, P. C.
    Ito, S.
    ARCHIVES OF DISEASE IN CHILDHOOD, 2009, 94 (12) : 981 - 982
  • [40] Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy
    Yu, Qian-Qian
    Qiu, Hong
    Zhang, Ming-Sheng
    Hu, Guang-Yuan
    Liu, Bo
    Huang, Liu
    Liao, Xin
    Li, Qian-Xia
    Li, Zhi-Huan
    Yuan, Xiang-Lin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (16) : 4250 - 4258
12345